/
COMSTECH-NTD NETWORK JOINT LECTURE SERIES COMSTECH-NTD NETWORK JOINT LECTURE SERIES

COMSTECH-NTD NETWORK JOINT LECTURE SERIES - PowerPoint Presentation

holly
holly . @holly
Follow
64 views
Uploaded On 2024-01-29

COMSTECH-NTD NETWORK JOINT LECTURE SERIES - PPT Presentation

Professor Patrick G Steel Department of Chemistry and Biophysical Sciences Institute Durham University Durham DH1 3LE UK Identifying and Validating New Drug Targets for Neglected Tropical Diseases ID: 1042686

target drug major network drug target network major targets trypanosoma tropical https org kinetoplastid leishmania comstech identified identify people

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "COMSTECH-NTD NETWORK JOINT LECTURE SERIE..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

1. COMSTECH-NTD NETWORK JOINT LECTURE SERIES Professor Patrick G. Steel Department of Chemistry and Biophysical Sciences Institute, Durham University, Durham DH1 3LE, UKIdentifying and Validating New Drug Targets for Neglected Tropical DiseasesRegister to attend:https://forms.gle/LaRnELNEZ9K9u6Ai8A Global Network for Neglected Tropical DiseasesChagas disease | Leishmaniasis https://ntd-network.org | @FillingVhttps://www.comstech.org/ The protozoan kinetoplastid parasites Leishmania spp, Trypanosoma brucei and Trypanosoma cruzi are responsible for potentially fatal diseases that affect over 22 million people worldwide, with an estimated 450 million people at risk. Current therapies are expensive and not widely accessible. In addition, drug toxicity and emerging resistance are major concerns and there is a major need for new tractable drug targets. In this presentation I will describe examples of phenotypic and target-based approaches towards the discovery of new leishmanial drug targets and the identification of tractable chemical starting points for future drug discovery programmes. For the former we have used a natural chalcone, with antileishmanial properties, as a starting point to develop and apply probes to identify the molecular target. In the second, target-based, strategy, we have identified the essential kinetoplastid sphingolipid synthase (SLS) as an attractive pharmaceutical target due to the divergence of function compared with the mammalian orthologous. We have developed screening assays to identify potential inhibitors against the Leishmania major enzyme. One assay identified the OTC antihistamine clemastine fumarate as a potential antileishmanial and I will discuss our efforts to validate and exploit this finding. 27 September, 20212:30 PM Pak10:30 AM UK